August 11, 2022


Axsome Therapeutics Shows Improved Relative Price Performance; Still Shy Of Benchmark

2 min read
Axsome Therapeutics (AXSM) saw a welcome improvement to its Relative Strength (RS) Rating on Friday,...

Axsome Therapeutics (AXSM) saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 65 to 71.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This exclusive rating from Investor’s Business Daily measures share price action with a 1 (worst) to 99 (best) score. The score shows how a stock’s price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.

History reveals that the best stocks typically have an RS Rating of at least 80 as they launch their biggest climbs. See if Axsome Therapeutics can continue to rebound and hit that benchmark.

Looking For The Best Stocks To Buy And Watch? Start Here

Axsome Therapeutics is now considered extended and out of buy range after clearing a 28.80 buy point in a first-stage consolidation. See if the stock forms a new chart pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.

Axsome Therapeutics showed -32% earnings growth in its most recent report. Revenue increased 0%.

Axsome Therapeutics earns the No. 139 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls (AMPH) and United Therapeutics (UTHR) are also among the group’s highest-rated stocks.


Biotech And Pharmaceutical Industry And Stock News

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Find Top Stocks Near A Buy Point With IBD Leaderboard

Copyright © All rights reserved. | Newsphere by AF themes.